scios
said
thursday
suspended
development
drug
designed
reduce
need
dailysis
patients
kidney
failure
sparking
sharp
sell
company
stock.the
stock
slid
2.31
34
percent
4.375
nasdaq
1.9
million
shares
changed
hands
early
afternoon
trading.scios
said
test
drug
auriculin
failed
increase
filtering
capacity
kidneys
phase
iii
study.the
company
said
drug
developed
genentech
companies
discussing
future
collaboration
months.mountain
view
calif
based
scios
biopharmaceutical
company
engaged
discovery
development
manufacture
commercialization
novel
human
therapeutics
